Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
9.63
+0.03 (0.31%)
Jun 5, 2025, 4:00 PM - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Arcus Biosciences stock ranges from a low of $13 to a high of $44. The average analyst price target of $25.33 forecasts a 163.03% increase in the stock price over the next year.
Price Target: $25.33 (+163.03%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcus Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 11 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $24 → $22 | Buy | Maintains | $24 → $22 | +128.45% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $15 → $13 | Hold | Maintains | $15 → $13 | +34.99% | May 8, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $29 → $26 | Buy | Maintains | $29 → $26 | +169.99% | May 7, 2025 |
| Barclays | Barclays | Buy Maintains $29 → $14 | Buy | Maintains | $29 → $14 | +45.38% | Apr 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $24 | Hold → Strong Buy | Upgrades | $24 | +149.22% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
122.75M
from 258.00M
Decreased by -52.42%
Revenue Next Year
159.37M
from 122.75M
Increased by 29.83%
EPS This Year
-4.33
from -3.14
EPS Next Year
-4.46
from -4.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 210.0M | 297.9M | 389.0M | ||
| Avg | 122.8M | 159.4M | 245.2M | ||
| Low | 85.9M | 88.2M | 99.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -18.6% | 142.6% | 144.1% | ||
| Avg | -52.4% | 29.8% | 53.8% | ||
| Low | -66.7% | -28.1% | -37.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.52 | -2.79 | -1.02 | ||
| Avg | -4.33 | -4.46 | -3.87 | ||
| Low | -5.72 | -6.33 | -5.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.